Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a biotechnology company based in Salt Lake City, Utah, specializing in the development of innovative diagnostic tests for early prediction of preterm birth risk and other pregnancy complications. Sera's mission is to provide pivotal pregnancy information to improve maternal and neonatal health. The company's flagship product, the PreTRM® Test, offers a unique blood-based biomarker test that predicts the individualized risk of spontaneous premature delivery in asymptomatic singleton pregnancies, allowing for proactive clinical interventions.
Sera Prognostics leverages a proprietary platform integrating proteomics and bioinformatics to discover, develop, and commercialize predictive analytic products that address the unmet needs in women's health. The company is committed to enhancing prenatal care and has formed strategic partnerships, including collaboration with the Bill & Melinda Gates Foundation to make its technologies accessible in underserved regions worldwide.
As a private entity supported by a robust investor base, including renowned names like Domain Associates and InterWest Partners, Sera Prognostics has assembled an expert management team and board of directors with substantial experience in clinical development and women's healthcare diagnostics. Recent achievements include the company's addition to the preliminary list of the Russell 3000 and Russell Small-Cap 2000 indexes, reflecting its growing market presence.
Financially, Sera Prognostics reported a significant reduction in operating expenses in recent quarters, aligning its commercial strategy with current market dynamics. The company continues to focus on advancing its product pipeline, including the development of ambient whole blood collection methods to enhance lab efficiency and reduce costs. The overall strategic directives aim at broadening test adoption and improving health outcomes, ultimately reducing the healthcare costs associated with maternal and neonatal complications.
For the latest updates, financial results, and operational highlights, interested parties can access the company's investor relations page and register for upcoming conference calls.
Sera Prognostics (Nasdaq: SERA) presented data on the PreTRM® test-and-treat strategy at the ISPOR 2022 conference in Washington, DC. The study analyzed the effects of two intervention strategies on high-risk pregnancies using the PreTRM® Test. Results showed a significant reduction in neonatal hospital stays by 22% and maternal stays by 8.5%. Furthermore, moderate-to-severe neonatal morbidity dropped by 29%. The findings highlight the economic benefits and potential cost savings of proactive interventions in pregnancy care.
Sera Prognostics (Nasdaq: SERA) reported its Q1 2022 financial results, showing revenue of $38,000, up from $13,000 in Q1 2021. Operating expenses surged to $12.3 million, compared to $6.0 million a year earlier. The net loss increased to $12.2 million from $6.4 million. The company ended the quarter with approximately $64.1 million in cash and equivalents. Key highlights included a streamlined PreTRM® test ordering process and advancing clinical studies. The ongoing PRIME study aims to enhance neonatal outcomes and reduce healthcare costs.
Sera Prognostics, Inc. (NASDAQ: SERA) and the Newborn Foundation have partnered to launch the Every Mother, Every Baby Project aimed at reducing maternal and neonatal mortality linked to preterm birth. This initiative focuses on educating healthcare professionals and improving access to biomarker-based tests like Sera's PreTRM® test, crucial for identifying at-risk pregnancies. The project aims for equitable health outcomes by addressing policy frameworks and ensuring standardized testing reimbursement. Over 60% of infant deaths occur during the neonatal period, with preterm birth a significant contributor.
Sera Prognostics, Inc., the Pregnancy Company® (Nasdaq: SERA), will release its first quarter fiscal year 2022 financial results on May 10, 2022, after market close. A conference call and live webcast will follow at 5:00 p.m. ET to discuss operational highlights and financial metrics. Sera specializes in maternal and neonatal health through innovative diagnostics like the PreTRM® test, which predicts preterm birth risk. The company aims to improve pregnancy outcomes and reduce healthcare costs associated with complications of prematurity.
Sera Prognostics announced the appointment of Dr. Jane F. Barlow to its Board of Directors, effective April 12, 2022. Dr. Barlow is recognized for her executive experience in health services and consulting, including roles as CEO of her own firm and Chief Clinical Officer at Real Endpoints. Her expertise is expected to bolster Sera's mission to enhance maternal and neonatal health with innovative diagnostics, including the PreTRM® test, which identifies preterm birth risk. CEO Gregory C. Critchfield highlighted Dr. Barlow's potential contributions towards improving healthcare outcomes and reducing costs.
Sera Prognostics Inc. (SERA) reported its Q4 and full-year 2021 financial results, highlighting a revenue increase to $26,000 in Q4 2021 from $6,000 in Q4 2020 and $82,000 for the full year compared to $25,000 in 2020. Operating expenses rose significantly, totaling $12.6 million in Q4, primarily due to increased commercial operations and R&D costs. The company reported a net loss of $12.5 million for Q4 2021, up from $5.4 million in the previous year. Sera also announced new partnerships and ongoing market expansion efforts aimed at improving the adoption of its PreTRM® Test.
Sera Prognostics (Nasdaq: SERA) presented findings at the 69th Annual Meeting of the Society for Reproductive Investigation. The study analyzed over 10,500 patients to evaluate the prediction of preeclampsia using 31 protein biomarkers and 6 clinical factors. Key results showed that previous preeclampsia was a strong predictor, while 7 biomarkers effectively predicted preeclampsia and 5 predicted preterm preeclampsia. The study highlights Sera's commitment to improving maternal health through innovative diagnostics.
Sera Prognostics (Nasdaq: SERA), dedicated to enhancing maternal and neonatal health, will release its fourth quarter and full year 2021 financial results on March 29, 2022, post-market close. A conference call will follow at 5:00 p.m. ET to discuss the results and operational highlights. The PreTRM® Test, a key product, predicts preterm birth risk with a focus on reducing healthcare costs associated with prematurity. The company highlights its commitment to addressing the serious issue of preterm births, which affect over one in ten infants.
Sera Prognostics, dedicated to enhancing maternal and neonatal health, will present at two upcoming virtual conferences: the 42nd Annual Cowen Health Care Conference on March 8, 2022, and the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022. CEO Gregory C. Critchfield will share company updates and latest achievements. The presentations will be accessible via webcast on the Sera Prognostics website. The company focuses on early prediction of preterm birth risks through its PreTRM® Test, aiming to improve healthcare outcomes for women and infants.
Sera Prognostics Inc. (Nasdaq: SERA) announced the rescheduling of its presentation at the virtual Citi 2022 Healthcare Conference, now set for February 24, 2022, at 9:30 a.m. EST. CEO Gregory C. Critchfield will provide an update and discuss recent achievements. A live webcast will be available on Sera's website, although no replay will be offered. Sera Prognostics is dedicated to enhancing maternal and neonatal health, focusing on early prediction of preterm birth risks through its PreTRM® Test, aimed at enabling proactive interventions.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
What is Sera Prognostics' main product?
Where is Sera Prognostics headquartered?
What is the mission of Sera Prognostics?
Who are some of the major investors in Sera Prognostics?
What recent financial milestone has Sera Prognostics achieved?
How does the PreTRM® Test work?
What are the benefits of the PreTRM® Test?
What strategic partnerships does Sera Prognostics have?
What are the company's future plans for expanding its product offerings?
What challenges does Sera Prognostics face?
